#Checkmate238 - Twitter Hashtag

8 months ago

New findings from the #CheckMate238 trial highlight #nivolumab's superior long-term efficacy over #ipilimumab in treating advanced melanoma. #ESMO25 https://t.co/n6TKX2L1yt

0

2

0

394

Oncology News Central @OncNewsCentral

about 1 year ago

Adjuvant anti-PD-1 therapy in stage II #Melanoma: treatment decisions are complex. Experts discuss #CheckMate238 results and how they individualize care. Featuring @DrBetofMDPhD, Amaria, and @DrSapnaPatel. https://t.co/HFe34QxtHs #Immunotherapy @MDAndersonNews

0

6

2

0

615

VJ Oncology

@VJOncology

over 5 years ago

#SkinCancer updates at #ESMO20: Jeffrey Weber of @nyulangone discusses the 4-year results from the #CheckMate238 trial Watch the full video here: 👉https://t.co/u8RscD5gsy👈 @VJOncology @myESMO @OncoAlert #OncoAlert #CTsm #MelSM #SkcSM

0

4

2

0

Angela Steen @angesteen

about 7 years ago

Reminder : why access to #immunotherapy (here Nivo) for ALL Stage III #melanoma patients in Ireland matters - #Checkmate238 shows 50% improvement of relapse free survival for Nivo patients v placebo #accesstomedicines #twotiersystem #nivolumab #eado2019

angesteen's tweet photo. Reminder : why access to #immunotherapy (here Nivo) for ALL Stage III #melanoma patients in Ireland matters - #Checkmate238 shows 50% improvement of relapse free survival for Nivo patients v placebo #accesstomedicines #twotiersystem #nivolumab #eado2019 https://t.co/ursNSrDKtq

0

6

10

0

VJ Oncology

@VJOncology

almost 8 years ago

VIDEO: @PAscierto discusses #Melanoma advancements: #Immunotherapy in the #Adjuvant setting: https://t.co/8iGtHBNTou @ASCO #ASCO18 #SkinCancer #Melsm #CheckMate238 #ClinicalTrials #CTSM #ImmunoOnc #Antibodies #CheckpointInhibitors #TargetedTherapy #Skcsm #Immunology

0

3

2

0

Oncology Tube

@oncologytube

almost 8 years ago

#Melanoma trial updates from ASCO 2018: CheckMate 238, KEYNOTE-001/006 & COLUMBUS @PAscierto @VJOncology #CheckMate238 https://t.co/c0LMV32aXU

oncologytube's tweet photo. #Melanoma trial updates from ASCO 2018: CheckMate 238, KEYNOTE-001/006 & COLUMBUS @PAscierto @VJOncology #CheckMate238 https://t.co/c0LMV32aXU https://t.co/1BXAt0agBP

0

3

1

0

Filip Janku

@FilipJankuMD

about 8 years ago

Results of adjuvant studies in melanoma #checkmate238 (nivo vs. ipi) and #keynote054 (pembro vs. placebo) support “Coke and Pepsi” theory as far checkpoint inh bigots are concerned #AACR2018